AQUESTIVE THERAPEUTICS INC (AQST) Stock Fundamental Analysis
USA - NASDAQ:AQST - US03843E1047 - Common Stock
6.025 USD
-0.1 (-1.71%)
Overall AQST gets a fundamental rating of 2 out of 10. We evaluated AQST against 192 industry peers in the Pharmaceuticals industry. AQST may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AQST is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year AQST has reported negative net income.
AQST had a negative operating cash flow in the past year.
In the past 5 years AQST always reported negative net income.
AQST had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of AQST (-69.42%) is worse than 67.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.42% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 61.09%, AQST is doing good in the industry, outperforming 70.31% of the companies in the same industry.
AQST's Gross Margin has improved in the last couple of years.
AQST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
2. Health
2.1 Basic Checks
AQST does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AQST has been increased compared to 1 year ago.
The number of shares outstanding for AQST has been increased compared to 5 years ago.
The debt/assets ratio for AQST has been reduced compared to a year ago.
2.2 Solvency
AQST has an Altman-Z score of -3.94. This is a bad value and indicates that AQST is not financially healthy and even has some risk of bankruptcy.
AQST has a Altman-Z score of -3.94. This is comparable to the rest of the industry: AQST outperforms 42.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.94 |
ROIC/WACCN/A
WACC9.37%
2.3 Liquidity
AQST has a Current Ratio of 3.53. This indicates that AQST is financially healthy and has no problem in meeting its short term obligations.
AQST has a Current ratio (3.53) which is comparable to the rest of the industry.
AQST has a Quick Ratio of 3.18. This indicates that AQST is financially healthy and has no problem in meeting its short term obligations.
AQST's Quick ratio of 3.18 is in line compared to the rest of the industry. AQST outperforms 59.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.53 | ||
| Quick Ratio | 3.18 |
3. Growth
3.1 Past
The earnings per share for AQST have decreased strongly by -61.36% in the last year.
AQST shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.80%.
AQST shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.82% yearly.
EPS 1Y (TTM)-61.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
Revenue 1Y (TTM)13.8%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-5.41%
3.2 Future
The Earnings Per Share is expected to grow by 19.83% on average over the next years. This is quite good.
Based on estimates for the next years, AQST will show a very strong growth in Revenue. The Revenue will grow by 32.17% on average per year.
EPS Next Y-26.63%
EPS Next 2Y-24.97%
EPS Next 3Y14.72%
EPS Next 5Y19.83%
Revenue Next Year-23.42%
Revenue Next 2Y7.67%
Revenue Next 3Y18.11%
Revenue Next 5Y32.17%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AQST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AQST. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as AQST's earnings are expected to grow with 14.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.97%
EPS Next 3Y14.72%
5. Dividend
5.1 Amount
AQST does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:AQST (11/7/2025, 2:46:59 PM)
6.025
-0.1 (-1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners39.24%
Inst Owner Change2.39%
Ins Owners4.64%
Ins Owner Change-1.5%
Market Cap726.62M
Revenue(TTM)57.56M
Net Income(TTM)-65.04M
Analysts83.75
Price Target9.15 (51.87%)
Short Float %11.04%
Short Ratio3.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.97%
Min EPS beat(2)-38.41%
Max EPS beat(2)18.46%
EPS beat(4)1
Avg EPS beat(4)-14.46%
Min EPS beat(4)-38.41%
Max EPS beat(4)18.46%
EPS beat(8)3
Avg EPS beat(8)-5.6%
EPS beat(12)7
Avg EPS beat(12)3.33%
EPS beat(16)11
Avg EPS beat(16)6.54%
Revenue beat(2)0
Avg Revenue beat(2)-21.73%
Min Revenue beat(2)-30.1%
Max Revenue beat(2)-13.36%
Revenue beat(4)1
Avg Revenue beat(4)-14.54%
Min Revenue beat(4)-30.1%
Max Revenue beat(4)4.68%
Revenue beat(8)2
Avg Revenue beat(8)-1.6%
Revenue beat(12)6
Avg Revenue beat(12)1.44%
Revenue beat(16)10
Avg Revenue beat(16)5.85%
PT rev (1m)2.25%
PT rev (3m)6.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.31%
EPS NY rev (1m)0%
EPS NY rev (3m)10.75%
Revenue NQ rev (1m)1.95%
Revenue NQ rev (3m)6.13%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)-0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 16.46 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.37
BVpS-0.6
TBVpS-0.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.42% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.09% | ||
| FCFM | N/A |
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
F-Score1
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 57.61% | ||
| Cap/Sales | 0.76% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.53 | ||
| Quick Ratio | 3.18 | ||
| Altman-Z | -3.94 |
F-Score1
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)67.19%
Cap/Depr(5y)49.48%
Cap/Sales(3y)2.51%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
EPS Next Y-26.63%
EPS Next 2Y-24.97%
EPS Next 3Y14.72%
EPS Next 5Y19.83%
Revenue 1Y (TTM)13.8%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-5.41%
Revenue Next Year-23.42%
Revenue Next 2Y7.67%
Revenue Next 3Y18.11%
Revenue Next 5Y32.17%
EBIT growth 1Y-246.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-81.18%
EBIT Next 3Y29%
EBIT Next 5Y37.98%
FCF growth 1Y-621.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-508.58%
OCF growth 3YN/A
OCF growth 5YN/A
AQUESTIVE THERAPEUTICS INC / AQST FAQ
What is the fundamental rating for AQST stock?
ChartMill assigns a fundamental rating of 2 / 10 to AQST.
Can you provide the valuation status for AQUESTIVE THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to AQUESTIVE THERAPEUTICS INC (AQST). This can be considered as Overvalued.
How profitable is AQUESTIVE THERAPEUTICS INC (AQST) stock?
AQUESTIVE THERAPEUTICS INC (AQST) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for AQST stock?
The Earnings per Share (EPS) of AQUESTIVE THERAPEUTICS INC (AQST) is expected to decline by -26.63% in the next year.